TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
LobSor Pharmaceuticals AB
Closing information (x1000 SEK)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
120,881
|
86,393 | |
| Financial expenses |
265,321
|
0 | |
| Earnings before taxes |
-170,372
|
79,159 | |
| EBITDA |
208,095
|
76,340 | |
| Total assets |
1,916,965
|
186,402 | |
| Current assets |
118,245
|
154,778 | |
| Current liabilities |
447,073
|
91,265 | |
| Equity capital |
174,727
|
95,137 | |
| - share capital |
46
|
44 | |
| Employees (average) |
3
|
3
|
3 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
9.1%
|
51.0% | |
| Turnover per employee |
40,294
|
28,798 | |
| Profit as a percentage of turnover |
-140.9%
|
91.6% | |
| Return on assets (ROA) |
5.0%
|
42.5% | |
| Current ratio |
26.4%
|
169.6% | |
| Return on equity (ROE) |
-97.5%
|
83.2% | |
| Change turnover |
34,488
|
73,928 | |
| Change turnover % |
14%
|
40%
|
593% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.